Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]

被引:88
作者
Evans, D. Gareth R. [1 ,2 ,3 ]
机构
[1] St Marys Hosp, Dept Med Genet, Cent Manchester Fdn Trust, Manchester M13 0JH, Lancs, England
[2] Univ Manchester, Med Genet Res Grp, Reg Genet Serv, Manchester, Lancs, England
[3] Univ Manchester, Natl Mol Genet Reference Lab, Manchester, Lancs, England
关键词
NF2; vestibular schwannoma; meningioma; ependymoma; UNILATERAL VESTIBULAR SCHWANNOMA; TUMOR-SUPPRESSOR GENE; NERVOUS-SYSTEM TUMORS; GERM-LINE MUTATIONS; NATURAL-HISTORY; MOLECULAR CHARACTERIZATION; STEREOTACTIC RADIOSURGERY; PRESYMPTOMATIC DIAGNOSIS; FAMILIAL SCHWANNOMATOSIS; SOMATIC MOSAICISM;
D O I
10.1097/GIM.0b013e3181ac9a27
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Neurofibromatosis 2 is a dominantly inherited tumor predisposition syndrome caused by mutations in the NF2 gene on chromosome 22. Affected individuals inevitably develop schwannomas typically affecting both vestibular nerves leading to deafness. Rehabilitation with brainstem implants is improving this outcome. Schwannomas also occur on other cranial nerves, on spinal nerve roots, and on peripheral nerves. Meningiomas and ependymomas are other tumor features. In excess of 50% of patients represent new mutations and as many as one third are mosaic for the underlying disease causing mutation. Although truncating mutations (nonsense and frameshifts) are the most frequent germline event and cause the most severe disease, single and multiple exon deletions are common. A strategy for detection of the latter is vital for a sensitive analysis. NF2 represents a difficult management problem with most patients facing substantial morbidity and reduced life expectancy. Surgery remains the focus of current management, although watchful waiting and occasionally radiation treatment have a role. In the future, the development of tailored drug therapies aimed at the genetic level are likely to provide huge improvements for this devastating, life limiting condition. Genet Med 2009:11(9):599-610.
引用
收藏
页码:599 / 610
页数:12
相关论文
共 83 条
[11]   Predictors of the risk of mortality in neurofibromatosis 2 [J].
Baser, ME ;
Friedman, JM ;
Aeschliman, D ;
Joe, H ;
Wallace, AJ ;
Ramsden, RT ;
Evans, DGR .
AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (04) :715-723
[12]  
BASER ME, NEUROFIBROMATOSIS 2
[13]   Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis [J].
Boyd, C. ;
Smith, M. J. ;
Kluwe, L. ;
Balogh, A. ;
MacCollin, M. ;
Plotkin, S. R. .
CLINICAL GENETICS, 2008, 74 (04) :358-366
[14]   Renal vascular disease in neurofibromatosis type 2: association or coincidence? [J].
Cordeiro, NJV ;
Gardner, KR ;
Huson, SM ;
Stewart, H ;
Elston, JS ;
Howard, EL ;
Tullus, KO ;
Pike, MG .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2006, 48 (01) :58-59
[15]   Spinal tumors in neurofibromatosis Type 2. Is emerging knowledge of genotype predictive of natural history? [J].
Dow, G ;
Biggs, N ;
Evans, G ;
Gillespie, J ;
Ramsden, R ;
King, A .
JOURNAL OF NEUROSURGERY-SPINE, 2005, 2 (05) :574-579
[16]   Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? [J].
Evans, D. G. R. ;
Ramsden, R. T. ;
Gokhale, C. ;
Bowers, N. ;
Huson, S. M. ;
Wallace, A. .
CLINICAL GENETICS, 2007, 71 (04) :354-358
[17]   What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumors? [J].
Evans, D. Gareth R. ;
Ramsden, Richard T. ;
Shenton, Andrew ;
Gokhale, Carolyn ;
Bowers, Naomi ;
Huson, Susan M. ;
Wallace, Andrew J. .
JOURNAL OF NEUROSURGERY, 2008, 108 (01) :92-96
[18]  
EVANS DG, 2009, CLIN CANCER RES, DOI DOI 10.1158/1078-0432
[19]   Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes [J].
Evans, DGR ;
Birch, JM ;
Ramsden, RT ;
Sharif, S ;
Baser, ME .
JOURNAL OF MEDICAL GENETICS, 2006, 43 (04) :289-294
[20]   Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: Higher incidence than previously thought [J].
Evans, DGR ;
Moran, T ;
King, A ;
Saeed, S ;
Gurusinghe, J ;
Ramsden, R .
OTOLOGY & NEUROTOLOGY, 2005, 26 (01) :93-97